{'fraction_non_alphanumeric': 0.0259009009009009, 'fraction_numerical': 0.02027027027027027, 'mean_word_length': 5.442028985507246, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Osimertinib 160 mg daily for advanced non‐small cell lung cancer with leptomeningeal metastasis: A case report

Advanced non‐small cell lung cancer (NSCLC) with leptomeningeal metastases (LM) is associated with a dismal prognosis of typically 3‐9 months. In preclinical and clinical studies, the third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib has demonstrated activity in the central nervous system (CNS), and studies are ongoing. We report here a case of osimertinib used at 160 mg once daily in a heavily pretreated patient with EGFR exon 20 T790M‐negative advanced NSCLC with LM to achieve a partial response, including shrinkage of the LM, for up to 12 months until further progression. The case suggests the feasibility of using osimertinib at a twofold standard dose to treat CNS metastases, irrespective of the T790M mutation status.